8:00 am - 8:15 am |
Welcome and Meeting Introduction
![Click to view presentation Click to view presentation](/images/icn_video.gif) Jon M. Wigginton, MD - Merck & Co., Inc. |
8:15 am - 11:30 am |
State of the Science (*) indicates presenting co-chair
Moderator: Thomas F. Gajewski, MD, PhD - University of Chicago |
8:15 am - 9:00 am |
Immunotherapy and Immunotherapy Combinations
Co-Chairs:
![Click to view presentation Click to view presentation](/images/icn_video.gif) Thomas F. Gajewski, MD, PhD - University of Chicago (*)
Jon M. Wigginton, MD - Merck & Co., Inc.
Panelists:
Lieping Chen, MD, PhD - Johns Hopkins University School of Medicine
Glenn Dranoff, MD - Dana-Farber Cancer Institute |
9:00 am - 9:45 am |
Angiogenesis and Immunotherapy Combinations
Co-Chairs:
![Click to view presentation Click to view presentation](/images/icn_video.gif) George Coukos, MD, PhD - University of Pennsylvania Medical Center (*)
Heinz Zwierzina, MD - Innsbruck Medical University
Panelists:
Michael B. Atkins, MD - Beth Israel Deaconess Medical Center
Steven K. Libutti, MD - National Cancer Institute |
9:45 am - 10:00 am |
BREAK |
10:00 am - 10:45 am |
Apoptosis Induction and Immunotherapy
Co-Chairs:
James H. Finke, PhD - Cleveland Clinic Foundation
![Click to view presentation Click to view presentation](/images/icn_video.gif) Peter Hersey, MD, PhD - University of Newcastle (*)
Panelists:
Douglas R. Green, PhD - St. Jude Children's Research Hospital
James W. Mier, MD - Beth Israel Deaconess Medical Center |
10:45 am - 11:30 am |
Cytotoxic Chemotherapy and Immunotherapy
Co-Chair:
![Click to view presentation Click to view presentation](/images/icn_video.gif) Ronald E. Gress, MD - NCI, NIH(*)
Panelists:
Bruce Blazar, MD - University of Minnesota
Leisha A. Emens, MD, PhD - Johns Hopkins University |
11:30 am - 12:00 pm |
Lunch |
12:00 pm - 1:30 pm |
Concurrent Session: Breakout Sessions (*) indicates the co-chair leading the session
(Pre-registration and ticket required for all breakout sessions) |
|
Breakout 1: Immunotherapy and Immunotherapy Combinations (Green ticket required)
Co-Chairs:
Thomas F. Gajewski, MD, PhD - University of Chicago
Jon M. Wigginton, MD - Merck & Co., Inc. (*)
Breakout 2: Angiogenesis and Immunotherapy Combinations (Yellow ticket required)
Co-Chairs:
George Coukos, MD, PhD - University of Pennsylvania Medical Center
Heinz Zwierzina, MD - Innsbruck Medical University (*)
Breakout 3: Apoptosis Induction and Immunotherapy (Blue ticket required)
Co-Chairs:
James H. Finke, PhD - Cleveland Clinic Foundation (*)
Peter Hersey, MD, PhD - University of Newcastle
Breakout 4: Cytotoxic Chemotherapy and Immunotherapy (Red ticket required)
Co-Chairs:
Hyam I. Levitsky, MD - Johns Hopkins University School of Medicine
Ronald E. Gress, MD - NCI, NIH (*)
|
|
|
|
12:00 pm - 1:30 pm |
Concurrent Group Lecture: Abstract Presentations
Co-Chairs:
Anne Letsch, MD - Chaité, Campus Benjamin Franklin
David F. McDermott, MD - Beth Israel Deaconess Medical Center |
12:00 PM - 12:15 PM |
Anti-PD-1 Antibody Enhances the Potency of GM-CSF-Secreting Tumor Cell Immunotherapies by Augmenting Immunotherapy-Induced Tumor-Specific T-Cell Responses
Betty Li - Cell Genesys, Inc. |
12:15 PM - 12:30 PM |
Expression of VEGFR-2 by Human Melanoma Cells Confers Synergistic Inhibition of Proliferations by Avastin and Rapamycin
Kerrington R. Molhoek, PhD - University of Virginia |
12:30 PM - 12:45 PM |
The Raf Kinase Inhibitor Sorafenib Inhibits Jak-STAT Signal Transduction in Human Immune Cells
Ene T. Raig - The Ohio State University |
12:45 PM - 1:00 PM |
Cyclophosphamide and Fludarabine Treatment Prior to Reconstitution with PBMC Does Not Reduce the Frequency of Circulating FoxP3+ Cells in Vaccinated Prostate Cancer Patients
James Thompson, PhD - Earle A. Chiles Research Institute |
1:00 PM - 1:15 PM |
Treatment of Established Tumors with Peritumoral Injections of CD40 Ligand (CD40L), CpG, poly(I:C), and Extracellular ATP in Murine Models
Richard S. Kornbluth, MD, PhD - University of California San Diego |
1:15 PM - 1:30 PM |
GITR Ligation and CD4+ T-Cell Combination Therapy Eradicates an Aggressive Solid Tumor by Concomitantly Enhancing Antitumor Immunity While Inhibiting Treg Suppressive Activity
Zhaoyang You, PhD - University of Pittsburgh School of Medicine |
1:45 pm - 2:45 pm |
Plenary Session: Perspectives on Combination Therapy
Moderator: Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
|
Regulatory Perspective
Speaker: ![Click to view presentation Click to view presentation](/images/icn_video.gif) Ashok Batra, MD - Food and Drug Administration |
|
Industry Perspective
Speaker: ![Click to view presentation Click to view presentation](/images/icn_video.gif) Geoffrey M. Nichol, MBChB, MBA - Medarex, Inc |
|
Legal Perspective
Speaker: ![Click to view presentation Click to view presentation](/images/icn_video.gif) Andrew D. Barofsky, JD, MBA - Oregon Biomedical Engineering Institute, Inc. |
2:45 pm - 4:45 pm |
Breakout Session Reports/Panel Discussions
Moderator: Rachel W. Humphrey, MD - Bristol-Myers Squibb |
2:45 pm - 3:15 pm |
Breakout 1 Report: Immunotherapy and Immunotherapy Combinations
![Click to view presentation Click to view presentation](/images/icn_video.gif) Jon M. Wigginton, MD - Merck & Co., Inc. |
3:15 pm - 3:45 pm |
Breakout 2 Report: Angiogenesis and Immunotherapy Combinations
![Click to view presentation Click to view presentation](/images/icn_video.gif) Heinz Zwierzina, MD - Innsbruck Medical University |
3:45 pm - 4:15 pm |
Breakout 3 Report: Apoptosis Induction and Immunotherapy
![Click to view presentation Click to view presentation](/images/icn_video.gif) James H. Finke, PhD - Cleveland Clinic Foundation |
4:15 pm - 4:45 pm |
Breakout 4 Report: Cytotoxic Chemotherapy and Immunotherapy
![Click to view presentation Click to view presentation](/images/icn_video.gif) Ronald E. Gress, MD - NCI, NIH |
4:45 pm - 5:00 pm |
Closing Comment and Future Plans |